nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—Hodgkin's disease lymphocyte depletion type stage unspecified—Cyclosporine—focal segmental glomerulosclerosis	0.0925	0.102	CcSEcCtD
Maraviroc—Hodgkin's disease—Cyclosporine—focal segmental glomerulosclerosis	0.0925	0.102	CcSEcCtD
Maraviroc—Hodgkin's disease lymphocyte predominance type stage unspecified—Cyclosporine—focal segmental glomerulosclerosis	0.0925	0.102	CcSEcCtD
Maraviroc—Consciousness abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.0503	0.0555	CcSEcCtD
Maraviroc—Polyneuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.0267	0.0295	CcSEcCtD
Maraviroc—Non-Hodgkin's lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.0249	0.0275	CcSEcCtD
Maraviroc—Lymphoma—Cyclosporine—focal segmental glomerulosclerosis	0.0249	0.0275	CcSEcCtD
Maraviroc—Altered state of consciousness—Cyclosporine—focal segmental glomerulosclerosis	0.0189	0.0208	CcSEcCtD
Maraviroc—Myositis—Cyclosporine—focal segmental glomerulosclerosis	0.0178	0.0196	CcSEcCtD
Maraviroc—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.0143	0.0158	CcSEcCtD
Maraviroc—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.0139	0.0153	CcSEcCtD
Maraviroc—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.013	0.0144	CcSEcCtD
Maraviroc—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.0116	0.0128	CcSEcCtD
Maraviroc—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.0113	0.0125	CcSEcCtD
Maraviroc—Coagulopathy—Cyclosporine—focal segmental glomerulosclerosis	0.0112	0.0124	CcSEcCtD
Maraviroc—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.0104	0.0114	CcSEcCtD
Maraviroc—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.0102	0.0113	CcSEcCtD
Maraviroc—CCR5—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.0102	0.108	CbGpPWpGaD
Maraviroc—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00985	0.0109	CcSEcCtD
Maraviroc—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00965	0.0107	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00959	0.0106	CcSEcCtD
Maraviroc—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00946	0.0104	CcSEcCtD
Maraviroc—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.00916	0.0101	CcSEcCtD
Maraviroc—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00847	0.00935	CcSEcCtD
Maraviroc—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00788	0.0087	CcSEcCtD
Maraviroc—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00788	0.0087	CcSEcCtD
Maraviroc—CCR5—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00784	0.0833	CbGpPWpGaD
Maraviroc—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00742	0.00819	CcSEcCtD
Maraviroc—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.00728	0.00803	CcSEcCtD
Maraviroc—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.00721	0.00796	CcSEcCtD
Maraviroc—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.00707	0.00781	CcSEcCtD
Maraviroc—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00707	0.00781	CcSEcCtD
Maraviroc—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00704	0.00777	CcSEcCtD
Maraviroc—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00704	0.00777	CcSEcCtD
Maraviroc—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.00657	0.00725	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—NOS2—focal segmental glomerulosclerosis	0.00595	0.0633	CbGpPWpGaD
Maraviroc—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00578	0.00638	CcSEcCtD
Maraviroc—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00572	0.00631	CcSEcCtD
Maraviroc—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00551	0.00608	CcSEcCtD
Maraviroc—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00538	0.00594	CcSEcCtD
Maraviroc—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00536	0.00592	CcSEcCtD
Maraviroc—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.00526	0.00581	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00508	0.00561	CcSEcCtD
Maraviroc—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.0049	0.00541	CcSEcCtD
Maraviroc—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00488	0.00538	CcSEcCtD
Maraviroc—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00488	0.00538	CcSEcCtD
Maraviroc—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00486	0.00537	CcSEcCtD
Maraviroc—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00481	0.00531	CcSEcCtD
Maraviroc—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00479	0.00529	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00479	0.0509	CbGpPWpGaD
Maraviroc—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00478	0.00528	CcSEcCtD
Maraviroc—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00478	0.00528	CcSEcCtD
Maraviroc—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.00475	0.00525	CcSEcCtD
Maraviroc—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00475	0.00525	CcSEcCtD
Maraviroc—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00474	0.00523	CcSEcCtD
Maraviroc—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00461	0.00509	CcSEcCtD
Maraviroc—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00458	0.00505	CcSEcCtD
Maraviroc—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.00439	0.00484	CcSEcCtD
Maraviroc—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00434	0.0048	CcSEcCtD
Maraviroc—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00432	0.00477	CcSEcCtD
Maraviroc—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0043	0.00475	CcSEcCtD
Maraviroc—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00429	0.00474	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—AGTR2—focal segmental glomerulosclerosis	0.00404	0.043	CbGpPWpGaD
Maraviroc—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00397	0.00438	CcSEcCtD
Maraviroc—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00395	0.00436	CcSEcCtD
Maraviroc—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00387	0.00427	CcSEcCtD
Maraviroc—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00384	0.00423	CcSEcCtD
Maraviroc—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00381	0.00421	CcSEcCtD
Maraviroc—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00376	0.00415	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00375	0.0399	CbGpPWpGaD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00368	0.0392	CbGpPWpGaD
Maraviroc—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.00394	CcSEcCtD
Maraviroc—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00352	0.00389	CcSEcCtD
Maraviroc—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.00341	0.00377	CcSEcCtD
Maraviroc—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00333	0.00367	CcSEcCtD
Maraviroc—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.0033	0.00364	CcSEcCtD
Maraviroc—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00324	0.00358	CcSEcCtD
Maraviroc—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00323	0.00357	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00322	0.00356	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00321	0.0342	CbGpPWpGaD
Maraviroc—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00321	0.00354	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00312	0.0332	CbGpPWpGaD
Maraviroc—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00311	0.00343	CcSEcCtD
Maraviroc—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.00309	0.00341	CcSEcCtD
Maraviroc—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00305	0.00337	CcSEcCtD
Maraviroc—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00302	0.00333	CcSEcCtD
Maraviroc—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00296	0.00327	CcSEcCtD
Maraviroc—CCR5—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00288	0.0307	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00283	0.00313	CcSEcCtD
Maraviroc—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00281	0.00311	CcSEcCtD
Maraviroc—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00279	0.00308	CcSEcCtD
Maraviroc—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.0027	0.00298	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00269	0.00296	CcSEcCtD
Maraviroc—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00268	0.00296	CcSEcCtD
Maraviroc—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.00294	CcSEcCtD
Maraviroc—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00266	0.00294	CcSEcCtD
Maraviroc—CCR5—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.00259	0.0276	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00254	0.00281	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00247	0.0263	CbGpPWpGaD
Maraviroc—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.00271	CcSEcCtD
Maraviroc—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.00271	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00245	0.026	CbGpPWpGaD
Maraviroc—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00229	0.00253	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—TGFB1—focal segmental glomerulosclerosis	0.00229	0.0243	CbGpPWpGaD
Maraviroc—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00223	0.00246	CcSEcCtD
Maraviroc—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.0022	0.00243	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.00219	0.0232	CbGpPWpGaD
Maraviroc—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00213	0.00235	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.0021	0.0223	CbGpPWpGaD
Maraviroc—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00206	0.00227	CcSEcCtD
Maraviroc—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00198	0.00218	CcSEcCtD
Maraviroc—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.00216	CcSEcCtD
Maraviroc—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00196	0.00216	CcSEcCtD
Maraviroc—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00195	0.00215	CcSEcCtD
Maraviroc—CCR5—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00188	0.02	CbGpPWpGaD
Maraviroc—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00185	0.00204	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00174	0.0185	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.0016	0.017	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00139	0.0148	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.00138	0.0147	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00132	0.0141	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.00131	0.0139	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.00126	0.0134	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.00126	0.0133	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.0012	0.0128	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.00116	0.0124	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.00106	0.0113	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.00106	0.0112	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.00101	0.0108	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000966	0.0103	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000902	0.00958	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000819	0.0087	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000749	0.00795	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000746	0.00793	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000742	0.00789	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.00068	0.00722	CbGpPWpGaD
Maraviroc—CCR5—Disease—LPL—focal segmental glomerulosclerosis	0.00067	0.00712	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000624	0.00663	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000571	0.00606	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS2—focal segmental glomerulosclerosis	0.000524	0.00556	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000484	0.00514	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000469	0.00499	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000445	0.00472	CbGpPWpGaD
Maraviroc—CCR5—Disease—SERPINE1—focal segmental glomerulosclerosis	0.000441	0.00469	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000402	0.00427	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000371	0.00394	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000309	0.00328	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—focal segmental glomerulosclerosis	0.000278	0.00296	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000236	0.00251	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000195	0.00207	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	6.86e-05	0.000729	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	6.04e-05	0.000641	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.56e-05	0.000591	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	4.18e-05	0.000445	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	3.58e-05	0.00038	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	2.75e-05	0.000292	CbGpPWpGaD
